Close Menu

NEW YORK – Cardea Bio said on Tuesday that it has raised $6.5 million in an extension of its Series A financing round, bringing the total the company has raised in this Series A round to more than $20 million.

The new capital infusion was led by the life sciences and biotechnology focused investor 3E Bioventures Capital and was joined by existing investors. Cardea will use the proceeds to further develop its Transistor platform, significantly expand mass manufacturing, and further grow its commercial partnerships.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.